Alpha-lipoic acid ameliorates myocardial toxicity induced by doxorubicin

被引:31
作者
Al-Majed, AA [1 ]
Gado, AM [1 ]
Al-Shabanah, OA [1 ]
Mansour, MA [1 ]
机构
[1] King Saud Univ, Coll Pharm, Dept Pharmacol, Riyadh 11451, Saudi Arabia
关键词
doxorubicin; lactate dehydrogenase; creatine phosphokinase; alpha-lipoic acid; lipid peroxidation; cardiotoxicity; reduced glutathione;
D O I
10.1016/S1043661802002311
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effect of alpha-lipoic acid (LA) on the cardiotoxicity induced by doxorubicin (DOX) was investigated. A single dose of DOX (15 mg kg(-1), i.p) induced cardiotoxicity manifested biochemically by a significant elevation of serum creatine phosphokinase (CK; EC: 2.7.3.2) and lactate dehydrogenase (LDH; EC: 1. 1. 1.27) 48 h later. Moreover, cardiotoxicity was further confirmed by the significant increase in lipid peroxides measured as malondialdehyde (MDA), and significant decrease in protein thiols (Protein-SH) content in heart tissues. Administration of LA (100 mg kg(-1)) orally for 5 days before and 2 days after DOX injection produced a significant protection against cardiotoxicity induced by DOX. The amelioration of cardiotoxicity was evident by significant reductions in serum CK and LDH. Moreover, LA prevented the rise of MDA as well as the significant reduction of Protein-SH. These results may suggest that LA has a protective effect against cardiotoxicity induced by DOX and it may, therefore, improve the therapeutic index of DOX (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:499 / 503
页数:5
相关论文
共 50 条
[1]  
Al-Shabanah O, 1998, BIOCHEM MOL BIOL INT, V45, P419
[2]  
Al-Shabanah OA, 1998, J EXP CLIN CANC RES, V17, P193
[3]   PREVENTION OF DOXORUBICIN-INDUCED MYOCARDIAL AND HEMATOLOGICAL TOXICITIES IN RATS BY THE IRON CHELATOR DESFERRIOXAMINE [J].
ALHARBI, MM ;
ALGHARABLY, NM ;
ALSHABANAH, OA ;
ALBEKAIRI, AM ;
OSMAN, AMM ;
TAWFIK, HN .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1992, 31 (03) :200-204
[4]   Effect of DL-α-lipoic acid on tissue nucleic acid contents in aged rats [J].
Arivazhagan, P ;
Panneerselvam, C .
PHARMACOLOGICAL RESEARCH, 2000, 42 (03) :223-226
[5]   Deferiprone protects against doxorubicin-induced myocyte cytotoxicity [J].
Barnabé, N ;
Zastre, JA ;
Venkataram, S ;
Hasinoff, BB .
FREE RADICAL BIOLOGY AND MEDICINE, 2002, 33 (02) :266-275
[6]   The pharmacology of the antioxidant lipoic acid [J].
Biewenga, GP ;
Haenen, GRMM ;
Bast, A .
GENERAL PHARMACOLOGY, 1997, 29 (03) :315-331
[7]   ADRIAMYCIN - NEW ANTICANCER DRUG WITH SIGNIFICANT CLINICAL ACTIVITY [J].
BLUM, RH ;
CARTER, SK .
ANNALS OF INTERNAL MEDICINE, 1974, 80 (02) :249-259
[8]  
Borenshtein D, 2001, DIABETES-METAB RES, V17, P44, DOI 10.1002/1520-7560(0000)9999:9999&lt
[9]  
::AID-DMRR153&gt
[10]  
3.0.CO